MedTrace Logo

Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

NCT07576959 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 990

Last updated 2026-05-08

No results posted yet for this study

Summary

This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.

Conditions

  • HELICOBACTER PYLORI INFECTIONS

Interventions

DRUG

Bismuth Add-on to Vonoprazan Dual Therapy

bismuth, vonoprazan and amoxicillin for 14 days

DRUG

Vonoprazan dual therapy

vonoprazan and amoxicillin for 14 days

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-08
Primary Completion
2030-12-31
Completion
2032-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07576959 on ClinicalTrials.gov